99 results
Search Results
2. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.
3. Practical considerations for fluid resuscitation in cirrhosis.
4. Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis?
5. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply.
6. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find.
7. Editorial: Adequate protein intake is more crucial than the profile of amino acids intake for sarcopenia prevention during the earlier stages of liver cirrhosis.
8. Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?
9. Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis.
10. Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D—Authors' reply.
11. Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D.
12. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.
13. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed.
14. Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels—authors' reply.
15. Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels.
16. Editorial: how early should 'early TIPSS' be in cirrhosis with acute variceal bleeding?
17. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Authors' reply.
18. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do?
19. Review article: prognostic significance of body composition abnormalities in patients with cirrhosis.
20. Editorial: early TIPSS in patients with cirrhosis and acute variceal bleeding—the plot thickens!
21. Editorial: composite kidney outcomes in studies with patients with cirrhosis and AKI—Are we ready to "MAKE" the switch?
22. Editorial: in the era of effective antiviral therapy, long‐term dynamic endoscopic monitoring does not seem to be necessary for all CHB patients with compensated cirrhosis.
23. Letter: the diagnostic value of ultrasound‐based versus CT‐based sarcopenia measurement in cirrhosis – authors' reply.
24. Letter: the diagnostic value of ultrasound‐based versus CT‐based sarcopenia measurement in cirrhosis.
25. Letter: improved alanine aminotransferase level in patients with chronic hepatitis B without cirrhosis and low viral load treated with nucleotide/nucleoside analogues.
26. Letter: improve survival in variceal bleeding in cirrhosis—place pTIPS as early as possible after index bleed. Authorsʼ reply.
27. Letter: improve survival after variceal bleeding in cirrhosis—place pTIPS as early as possible after index bleed.
28. The association between hepatocellular carcinoma and direct‐acting anti‐viral treatment in patients with decompensated cirrhosis.
29. Letter: serum HBV RNA and HBcrAg may help to evaluate safely stopping nucleot(s)ide analogues in patients with HBeAg‐negative chronic hepatitis B and without cirrhosis.
30. Letter: hepatocellular carcinoma negatively affects sustained virological response of direct‐acting anti‐viral treatment in decompensated cirrhosis.
31. Letter: comparison of clinical prediction rules for ruling out cirrhosis in non‐alcoholic fatty liver disease (NAFLD).
32. Letter: long‐term abdominal drains in cirrhosis – a solution or a new problem?
33. Letter: long‐term abdominal drains in cirrhosis—a solution or a new problem? Authors' reply.
34. Letter: non‐selective beta‐blockers in cirrhosis—effect beyond portal hypertension. Authors' reply.
35. Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply.
36. Editorial: timing of carvedilol – promoting survivors in cirrhosis.
37. Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD – not everyone fits the mould.
38. Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis—towards abbreviated MRI alternative in patients with obesity? Authors' reply.
39. Editorial: hepatocellular carcinoma in non‐cirrhotic NASH—a troubling reality.
40. Editorial: when to start carvedilol in cirrhosis—time to reconsider? Authors' reply.
41. Editorial: when to start carvedilol in cirrhosis—time to reconsider?
42. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B‐related compensated cirrhosis—authors' reply.
43. Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B‐related compensated cirrhosis.
44. Editorial: stratifying risk of adverse outcomes in cirrhosis—the Hepquant SHUNT test. Authors' reply.
45. Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test.
46. Editorial: the polygenic risk of cirrhosis development.
47. Editorial: proton pump inhibitor use in cirrhosis—a piece of the puzzle. Authors' reply.
48. Editorial: proton pump inhibitor use in cirrhosis—a piece of the puzzle.
49. Editorial: Beta blockers and cirrhosis—more than just portal hypertension?
50. TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis—Authors' reply.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.